Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
info@chordiatherapeutics.com

This press release is an English translation of a Japanese-language press release. The
official language of this press release is Japanese, and the Japanese version takes
precedence over the English version in terms of content and interpretation.

<Press Release>12.12 2022
Chordia Therapeutics Announces Interim Results from the Phase I Clinical Trial andthe Non-clinical Study of CLK Inhibitor CTX-712 and the Results from the Nonclinical Study of MALT-1 Inhibitor CTX-177 Presented at the 2022 ASH AnnualMeeting.
Kanagawa, Japan, December 12, 2022 – Chordia Therapeutics Inc. (“Chordia”), abiotech company engaged in the research and development of novel therapies forcancers, today announced that it presented the interim results from the Phase I clinical
trial and the non-clinical study of CTX-712, a selective pan-CDC-like kinase (“CLK”)
inhibitor and the results from the non-clinical study of CTX-177 (ONO-7018),
MALT-1 inhibitor, at the 64th Annual Meeting of the American Society ofHematology (ASH) being held from December 10 to December 13.
In a cohort of patients with hematologic cancers in the Phase 1 clinical trial of CTX712, four complete remission (CR) and one complete remission with neutrophil failure(CRi) were observed in eight patients with acute myeloid leukemia andmyelodysplastic syndrome. This confirmed the POC (Proof of Concept) of the clinical
trial. A dose-dependent increase in systemic exposure was observed inpharmacokinetics (PK) analysis, and a dose-dependent increase in exon skipping ofRNAs used as pharmacodynamics (PD) markers confirmed mRNA splicing
modification by CTX-712. Further studies are currently underway to determine therecommended Phase 2 dosing.
“It is a great honor to be involved in the first-in-human clinical trial of a new
anticancer drug with a novel mechanism of action,” said Dr. Hisayuki Yokoyama,
Associate Professor of Hematology at Tohoku University Hospital and lead author ofthis presentation. “Although it is still in the early stage of clinical trials, we are pleased
that more than half of the patients with hematologic malignancy showed remission inthe clinical trial. We hope that CTX-712 will become an effective treatment forpatients with advanced, relapsed, or refractory malignancies in the future.”
ASH abstract number: 2763
Title: A First-in-Human Phase I Study of CTX-712 in Patients with Advanced,Relapsed or Refractory Malignant Tumors - Hematologic Malignancies Dose
Escalation Cohort
The following are the abstract numbers of the announcement made by the Company
and its collaborators regarding the pre-clinical studies of CTX-712 and CTX-177(ONO-7018).

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japaninfo@chordiatherapeutics.com

ASH abstract number: 202
Title: CTX-712, a Novel Splicing Modulator Targeting Myeloid Neoplasms
ASH abstract number: 4000
Title: Preclinical Translational Research Suggests a Clinical Trial Strategy for a Novel
MALT1 Inhibitor ONO-7018/CTX-177 Against Malignant Lymphomas
About CTX-712
CTX-712 is a first-in-class, orally available and selective small molecule inhibitor ofCLK, a key regulator of the RNA splicing process that plays an important role in cellgrowth. CTX-712 inhibits the growth of various human tumor cell lines in vitro and,in addition, exhibits antitumor activity in multiple xenograft mouse models in vivo.
Details of Phase 1 Clinical Trial
The Phase 1 clinical trial in Japan is investigating the tolerability, safety, andpharmacokinetics (PK) of CTX-712 in patients with advanced, relapsed, or refractory
malignancies. For details of the study, please refer to JapicCTI-184188.
About RNA Splicing
RNA immediately after transcription is called precursor messenger RNA whichcontains noncoding sequences (introns) as well as coding sequences (exons) that areneeded to make proteins. RNA splicing is a process to remove the introns and connect
the exons to form mature mRNA, which is then translated into protein.
About CDC-like Kinases (CLKs)
Kinase is a general term for enzymes that catalyze the transfer of phosphate groups inbiological substances, such as ATP, over to target substances that are called substrates.
Over 500 protein kinases are known in humans, of which the CLK family consists offour members – CLK1, CLK2, CLK3, and CLK4, and phosphorylates serine/argininerich (SR) proteins as substrates.
About Exon Skipping
When CTX-712 inhibits CLK kinases and the SR protein dephosphorylates, a splicing
change called exon skipping occurs, in which the exons fail to be incorporated into themature mRNA.
About CTX-177（ONO-7018）
CTX-177 (ONO-7018) is a selective inhibitor against a mucosa-associated lymphoidtissue lymphoma translocation protein 1 (MALT1), which is known to be involved in
intracellular signaling pathway in lymphocytic blood cells. Activation of MALT1 isreported to play an important role in malignancies of lymphocytes. CTX-177 (ONO7018) is expected to exert anti-tumor effect against these malignancies by inhibiting
MALT1 activity. CTX-177 (ONO-7018) is in Phase 1 study in the United States byour licensing partner, Ono Pharmaceutical Co., Ltd. For more information, please visit
the following website at clinicaltrials.gov/ (NCT05515406).

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
info@chordiatherapeutics.com

Important Notice
In this press release, the definition of “press release” covers any oral presentation,question and answer session, and written and/or oral materials discussed or distributedby Chordia Therapeutics in connection with this press release. This press release(including the oral description and related questions and answers) is not intended toconstitute, represent, or form part of any offer, invitation, or solicitation to purchase
and/or acquire anything, including securities.
Disclaimer
Any announcements by Chordia Therapeutics, including this press release, may
contain information on products derived from pharmaceutical developments, but areintended to inform the latest information related to Chordia’s business, and notintended as promotions, solicitations, advertisements, or to provide medical advice.
Forward-Looking Statements
This press release and materials distributed in connection with this press release may
contain forward-looking statements, information, beliefs, and opinions concerning ourfuture operations, future positioning, and performance, including estimates,
projections, goals, and plans. Forward-looking statements may include, but are notlimited to, expressions such as "goals," "plans," "beliefs," "hopes," "continues,""expects," "intends," "assures," "will," "may," "should," "would," "could," "estimates,""projects," and/or other similar expressions, or the negative thereof. These forwardlooking statements are based on assumptions concerning a number of important factors,
including the following, which could cause actual results to differ materially fromthose expressed or implied by the forward-looking statements; highly influential
factors that include economic conditions surrounding our global business, which
include general economic conditions in Japan and the United States, competitive
pressures and developments including changes in applicable laws and regulations,which include global healthcare reform, uncertainty as to our clinical success, andchallenges inherent in new product development (which include regulatory decisions
and their timing,) uncertainty as to the commercial success of new and existingproducts manufacturing difficulties, delays fluctuations in interest rates and exchange
rates claims or concerns regarding the safety or efficacy of commercial products or
product candidates the impact of a health crisis, such as the COVID-19 pandemic, on
Chordia and its customers and suppliers (including foreign governments in countries
in which the Company conducts business) or other aspects of its business. We
undertake no obligation to update any forward-looking statements contained in thispress release or any other forward-looking statements we may make, except as requiredby law or stock exchange rules. Past performance is not indicative of future operating
results, and any of our operating results or statements in this press release are notestimates, forecasts, warranties, or projections of our future operating results.
About Chordia Therapeutics
Chordia was established in November 2017 at Shonan Health Innovation Park(“Shonan iPark”) in Fujisawa, Kanagawa Prefecture, as a biotech company engaged
in the research and development of novel therapies for cancers, with the goal of

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
info@chordiatherapeutics.com

researching and developing first-in-class anti-cancer drugs and creating innovative
new drugs.
In addition to its leading program for CTX-712, Chordia is engaged in the research of
several developments in our pipeline, including CTX-439, a CDK12 inhibitor, whichis expected to be effective in cancers with specific abnormalities, as well as GCN2inhibitors.
Established:
Address:
Representative:
Website:November 2017
26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Hiroshi Miyake, Representative Director
https://www.chordiatherapeutics.com/en/

For more information, please contact IR: info@chordiatherapeutics.com